Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD44 | P16070 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | AR | P10275 | 1/20 | 0.36 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.35 |
| ▸ | KHK | P50053 | 1/20 | 0.35 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.35 |
| ▸ | KDM1A | O60341 | 5/20 | 0.34 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.34 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.33 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20045543 | 0.92 | GAA (0.44) | CD44GAANPC1ALDH1A1CYP3A4 | |
| SCHEMBL406316 | 0.83 | CD44 (0.58) | CD44GAAALDH1A1CYP3A4TSHR | |
| SCHEMBL1796492 | 0.82 | CD44 (0.42) | CD44GAAALDH1A1CYP3A4TSHR | |
| SCHEMBL6402873 | 0.82 | GAA (0.52) | GAANPC1ALDH1A1CYP3A4TSHR | |
| SCHEMBL6948318 | 0.82 | TSHR (0.41) | ALDH1A1TSHRMAPK1ARTRPV4 | |
| SCHEMBL19931598 | 0.80 | CD44 (0.41) | CD44ALDH1A1CYP3A4TSHRMAPK1 | |
| SCHEMBL7024058 | 0.80 | TSHR (0.52) | CD44NPC1ALDH1A1CYP3A4TSHR | |
| SCHEMBL30498666 | 0.80 | GAA (0.57) | CD44GAANPC1ALDH1A1CYP3A4 | |
| SCHEMBL7073779 | 0.80 | GAA (0.57) | CD44GAANPC1ALDH1A1CYP3A4 | |
| SCHEMBL31314338 | 0.76 | GAA (0.50) | GAANPC1ALDH1A1CYP3A4TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10752624-B2 | Kinase inhibitors | ORIGENIS GMBH (DE) | 2020-08-25 | — | — | US | disclosed |
| US-20180305356-A1 | NOVEL KINASE INHIBITORS | ORIGENIS GMBH (DE) | 2018-10-25 | — | — | US | disclosed |
| US-10000482-B2 | Kinase inhibitors | ORIGENIS GMBH (DE) | 2018-06-19 | — | — | US | disclosed |
| EP-2807152-B1 | AMINOPYRIMIDINE DERIVATIVES AS LRRK2 MODULATORS | GENENTECH INC (US) | 2017-07-19 | — | — | EP | disclosed |
| EP-2785709-B1 | AMINOPYRIMIDINE DERIVATIVES AS LRRK2 MODULATORS | GENENTECH INC (US) | 2017-05-10 | — | — | EP | disclosed |
| EP-2785709-B1 | AMINOPYRIMIDINE DERIVATIVES AS LRRK2 MODULATORS | GENENTECH INC (US) | 2017-05-10 | — | — | EP | disclosed |
| US-9637491-B2 | Pyrazolo[4,3-D]pyrimidines as kinase inhibitors | ORIGENIS GMBH (DE) | 2017-05-02 | — | — | US | disclosed |
| EP-3121173-A1 | AMINOPYRIMIDINE DERIVATIVES AS LRRK2 MODULATORS | F. Hoffmann-La Roche AG (CH) | 2017-01-25 | — | — | EP | disclosed |
| EP-3121173-A1 | AMINOPYRIMIDINE DERIVATIVES AS LRRK2 MODULATORS | F. Hoffmann-La Roche AG (CH) | 2017-01-25 | — | — | EP | disclosed |
| US-9145402-B2 | Aminopyrimidine derivatives as LRRK2 modulators | GENENTECH, INC. (US) | 2015-09-29 | — | — | US | disclosed |
| EP-0518909-A1 | WATER-INSOLUBLE AZO DYES, THEIR MANUFACTURE AND USE. | HOECHST AG (DE) | 1992-12-23 | — | — | EP | disclosed |
| EP-0316649-B1 | WATER INSOLUBLE AZO COLOURING AGENTS, THEIR PREPARATION AND USE | HOECHST AKTIENGESELLSCHAFT (DE) | 1992-07-22 | — | — | EP | disclosed |
| WO-1991013941-A1 | WATER-INSOLUBLE AZO DYES, THEIR MANUFACTURE AND USE | HOECHST AKTIENGESELLSCHAFT (DE) | 1991-09-19 | — | — | WO | disclosed |
| US-5026831-A | Water-insoluble disazo colorants having hetero-bicyclic methylene-active compounds as coupling component | HOECHST AKTIENGESELLSCHAFT (DE) | 1991-06-25 | — | — | US | disclosed |
| EP-0316649-A2 | Water insoluble azo colouring agents, their preparation and use | HOECHST AKTIENGESELLSCHAFT (DE) | 1989-05-24 | — | — | EP | disclosed |
| US-4224025-A | Process for the dyeing and printing of paper materials in different hues using a single coupling component | CIBA-GEIGY CORPORATION (US) | 1980-09-23 | — | — | US | disclosed |
| US-4168952-A | ACETOACETIC ACID ARYLAMIDE AS COUPLER | HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (DE) | 1979-09-25 | — | — | US | disclosed |
| US-4165967-A | HYDROXY-PYRIDINE OR PYRIDONE COUPLERS | HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (DE) | 1979-08-28 | — | — | US | disclosed |
| US-4162893-A | Process for dyeing human hair with diazo salts | HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (HENKEL KGAA) (DE) | 1979-07-31 | — | — | US | disclosed |
| US-4065254-A | DIAZO DYES, LEATHER, COTTON, WOOL | CIBA-GEIGY CORPORATION (US) | 1977-12-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180305356-A1 | NOVEL KINASE INHIBITORS | LRRK2, MYLK2, MYLK | CD44 3059/4885GAA 742/4885NPC1 4398/4885 |
| US-10000482-B2 | Kinase inhibitors | LRRK2, MYLK2, MYLK | CD44 2921/4885GAA 698/4885NPC1 4434/4885 |
| US-10752624-B2 | Kinase inhibitors | LRRK2, MYLK2, MYLK | CD44 2921/4885GAA 698/4885NPC1 4434/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.